
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8834590/publications.pdf

Version: 2024-02-01



FENC XIE

#	Article	IF	CITATIONS
1	A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Medical Care, 2016, 54, 98-105.	2.4	290
2	United States Valuation of EQ-5D-5L Health States Using an International Protocol. Value in Health, 2019, 22, 931-941.	0.3	204
3	Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2019, 321, 753.	7.4	176
4	Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores. Value in Health, 2017, 20, 644-650.	0.3	170
5	Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies. Pharmacoeconomics, 2016, 34, 1087-1100.	3.3	154
6	GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences—inconsistency, imprecision, and other domains. Journal of Clinical Epidemiology, 2019, 111, 83-93.	5.0	146
7	Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate?. Value in Health, 2010, 13, 487-494.	0.3	120
8	Validation of Chinese Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in patients scheduled for total knee replacement. Quality of Life Research, 2008, 17, 595-601.	3.1	95
9	Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. ClinicoEconomics and Outcomes Research, 2011, 3, 89.	1.9	84
10	Comparing EQ-5D Valuation Studies. Medical Decision Making, 2014, 34, 8-20.	2.4	84
11	GRADE Guidelines 30: the GRADE approach to assessing the certaintyÂof modeled evidence—An overview in the context of healthÂdecision-making. Journal of Clinical Epidemiology, 2021, 129, 138-150.	5.0	81
12	Systemic Therapy for Previously Untreated Advanced <i>BRAF</i> -Mutated Melanoma. JAMA Oncology, 2017, 3, 366.	7.1	68
13	Costâ€effectiveness of a collaborative dementia care management—Results of a clusterâ€randomized controlled trial. Alzheimer's and Dementia, 2019, 15, 1296-1308.	0.8	49
14	Use of a Disease-Specific Instrument in Economic Evaluations: Mapping WOMAC onto the EQ-5D Utility Index. Value in Health, 2010, 13, 873-878.	0.3	45
15	A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). Pharmacoeconomics, 2015, 33, 867-877.	3.3	45
16	Comparison of the EuroQol and short form 6D in Singapore multiethnic asian knee osteoarthritis patients scheduled for total knee replacement. Arthritis and Rheumatism, 2007, 57, 1043-1049.	6.7	43
17	Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. Journal of Clinical Oncology, 2015, 33, 2296-2302.	1.6	43
18	Cultural Values: Can They Explain Differences in Health Utilities between Countries?. Medical Decision Making, 2019, 39, 605-616.	2.4	42

#	Article	IF	CITATIONS
19	Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 349-357.	3.7	41
20	A Study on Indirect and Intangible Costs for Patients with Knee Osteoarthritis in Singapore. Value in Health, 2008, 11, S84-S90.	0.3	39
21	The excess burden of osteoarthritis in the province of Ontario, Canada. Arthritis and Rheumatism, 2012, 64, 1153-1161.	6.7	39
22	Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. Medical Care, 2014, 52, 935-943.	2.4	38
23	Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma. Cancer Treatment Reviews, 2019, 74, 43-48.	7.7	38
24	A Cost-Effectiveness Model Comparing Endovascular Repair to Open Surgical Repair of Abdominal Aortic Aneurysms in Canada. Value in Health, 2009, 12, 245-252.	0.3	37
25	Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Effectiveness and Resource Allocation, 2009, 7, 20.	1.5	35
26	Extension from inpatients to outpatients: validity and reliability of the Oxford Knee Score in measuring health outcomes in patients with knee osteoarthritis. International Journal of Rheumatic Diseases, 2011, 14, 206-210.	1.9	34
27	Cost effectiveness analysis of population-based serology screening and 13C-Urea breath test for Helicobacter pylori to prevent gastric cancer: A markov model. World Journal of Gastroenterology, 2008, 14, 3021.	3.3	34
28	Comparative performance of the EQ-5D-5L and SF-6D index scores in adults with type 2 diabetes. Quality of Life Research, 2017, 26, 2057-2066.	3.1	33
29	Evaluation of health outcomes in osteoarthritis patients after total knee replacement: a two-year follow-up. Health and Quality of Life Outcomes, 2010, 8, 87.	2.4	32
30	Experiences regarding nutrition and exercise among women during early postpartum: a qualitative grounded theory study. BMC Pregnancy and Childbirth, 2019, 19, 368.	2.4	32
31	Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best–worst scaling?. European Journal of Health Economics, 2014, 15, 281-288.	2.8	30
32	The Effect of Bariatric Surgery on Mobility, Health-Related Quality of Life, Healthcare Resource Utilization, and Employment Status. Obesity Surgery, 2017, 27, 349-356.	2.1	30
33	Direct and indirect costs of osteoarthritis in Singapore: a comparative study among multiethnic Asian patients with osteoarthritis. Journal of Rheumatology, 2007, 34, 165-71.	2.0	28
34	Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study. Quality of Life Research, 2016, 25, 1679-1685.	3.1	27
35	Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool. American Heart Journal, 2020, 224, 35-46.	2.7	27
36	True Difference or Something Else? Problems in Cost of Osteoarthritis Studies. Seminars in Arthritis and Rheumatism, 2007, 37, 127-132.	3.4	26

#	Article	IF	CITATIONS
37	The need for standardization: A literature review of indirect costs of rheumatoid arthritis and osteoarthritis. Arthritis and Rheumatism, 2008, 59, 1027-1033.	6.7	25
38	Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. International Journal of Technology Assessment in Health Care, 2008, 24, 87-95.	0.5	25
39	Illustrating Economic Evaluation of Diagnostic Technologies: Comparing Helicobacter pylori Screening Strategies in Prevention of Gastric Cancer in Canada. Journal of the American College of Radiology, 2009, 6, 317-323.	1.8	25
40	EQ-5D-derived health utilities and minimally important differences for chronic health conditions: 2011 Commonwealth Fund Survey of Sicker Adults in Canada. Quality of Life Research, 2016, 25, 3009-3016.	3.1	25
41	Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non–Small Cell Lung Cancer in China. Clinical Therapeutics, 2019, 41, 2308-2320.e11.	2.5	25
42	Do Health-Related Quality-of-Life Domains and Items in Knee and Hip Osteoarthritis Vary in Importance Across Social-Cultural Contexts? A Qualitative Systematic Literature Review. Seminars in Arthritis and Rheumatism, 2005, 34, 793-804.	3.4	24
43	Validity, Feasibility and Acceptability of Time Trade-Off and Standard Gamble Assessments in Health Valuation Studies: A Study in a Multiethnic Asian Population in Singapore. Value in Health, 2008, 11, S3-S10.	0.3	24
44	Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study. European Journal of Health Economics, 2010, 11, 27-34.	2.8	24
45	Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis. Pharmacoeconomics, 2013, 31, 501-508.	3.3	24
46	Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial. American Heart Journal, 2018, 199, 75-82.	2.7	24
47	Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study. American Heart Journal, 2018, 201, 149-157.	2.7	23
48	Robotic Versus Video-Assisted Thoracoscopic Lung Resection During Early Program Development. Annals of Thoracic Surgery, 2018, 105, 1050-1057.	1.3	22
49	Effect of patientâ€centered transitional care services on patientâ€reported outcomes in heart failure: sexâ€specific analysis of the <scp>PACTâ€HF</scp> randomized controlled trial. European Journal of Heart Failure, 2021, 23, 1488-1498.	7.1	22
50	Triple Therapy for the Management of COPD: A Review. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 8, 206-243.	1.6	21
51	Is bad living better than good death? Impact of demographic and cultural factors on health state preference. Quality of Life Research, 2016, 25, 979-986.	3.1	21
52	Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL). Health and Quality of Life Outcomes, 2018, 16, 78.	2.4	20
53	Health State Utility Assessment for Breast Cancer. Value in Health Regional Issues, 2012, 1, 93-97.	1.2	19
54	Be Healthy in Pregnancy (BHIP): A Randomized Controlled Trial of Nutrition and Exercise Intervention from Early Pregnancy to Achieve Recommended Gestational Weight Gain. Nutrients, 2022, 14, 810.	4.1	19

#	Article	IF	CITATIONS
55	Health Technology Assessment and Primary Data Collection for Reducing Uncertainty in Decision Making. Journal of the American College of Radiology, 2009, 6, 332-342.	1.8	18
56	Forty-two systematic reviews generated 23 items for assessing the risk of bias in values and preferences' studies. Journal of Clinical Epidemiology, 2017, 85, 21-31.	5.0	18
57	Structured diet and exercise guidance in pregnancy to improve health in women and their offspring: study protocol for the Be Healthy in Pregnancy (BHIP) randomized controlled trial. Trials, 2018, 19, 691.	1.6	17
58	Acceptability and Validity of the EQ-5D in Patients Living With Dementia. Value in Health, 2020, 23, 760-767.	0.3	17
59	Validation of the International Classification of Functioning, Disability, and Health (ICF) Brief Core Set for osteoarthritis. Scandinavian Journal of Rheumatology, 2008, 37, 450-461.	1.1	16
60	Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpura. Clinical Therapeutics, 2009, 31, 1082-1091.	2.5	15
61	Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection?. European Journal of Health Economics, 2015, 16, 847-855.	2.8	15
62	Population Norms for SF-6Dv2 and EQ-5D-5L in China. Applied Health Economics and Health Policy, 2022, 20, 573-585.	2.1	15
63	Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). Medical Decision Making, 2019, 39, 371-379.	2.4	14
64	Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis. Journal of Interventional Cardiac Electrophysiology, 2012, 35, 259-275.	1.3	13
65	Transforming Latent Utilities to Health Utilities: East Does Not Meet West. Health Economics (United) Tj ETQq1	1 0.78431 1.7	4 rgBT /Ove
66	Association of Roux-en-Y Gastric Bypass With Postoperative Health Care Use and Expenditures in Canada. JAMA Surgery, 2020, 155, e201985.	4.3	13
67	Calculating Utility Decrements Associated With an Adverse Event: Marginal Tobit and CLAD Coefficients Should Be Used With Caution. Medical Decision Making, 2011, 31, 790-799.	2.4	13
68	Industry sponsorship bias in cost effectiveness analysis: registry based analysis. BMJ, The, 0, , e069573.	6.0	13
69	How dead is dead? Qualitative findings from participants of combined traditional and lead-time time trade-off valuations. Quality of Life Research, 2016, 25, 35-43.	3.1	12
70	A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for Llving FEtuses (ILIFE) trial. Trials, 2020, 21, 771.	1.6	12
71	Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials. European Journal of Health Economics, 2020, 21, 717-728.	2.8	12
72	Association between progression-free survival and health-related quality of life in oncology: a systematic review protocol. BMJ Open, 2016, 6, e012909.	1.9	11

#	Article	IF	CITATIONS
73	Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility. Medical Decision Making, 2016, 36, 223-233.	2.4	11
74	Economic Considerations of Early Rule-In/Rule-Out Algorithms for The Diagnosis of Myocardial Infarction in The Emergency Department Using Cardiac Troponin and Glycemic Biomarkers. Clinical Chemistry, 2017, 63, 593-602.	3.2	11
75	FIT for FUNCTION: study protocol for a randomized controlled trial. Trials, 2018, 19, 39.	1.6	11
76	What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks. Value in Health, 2022, 25, 302-317.	0.3	11
77	Defining decision thresholds for judgments on health benefits and harms using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision (EtD) frameworks: a protocol for a randomised methodological study (GRADE-THRESHOLD). BMJ Open, 2022, 12. e053246.	1.9	11
78	Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 513-521.	1.4	10
79	Health economic evaluations help inform payers of the best use of scarce health care resources. International Journal of Circumpolar Health, 2011, 70, 419-427.	1.2	10
80	Behavioral activation group therapy for reducing depressive symptoms and improving quality of life: a feasibility study. Pilot and Feasibility Studies, 2016, 2, 22.	1.2	10
81	Underestimation of Variance of Predicted Health Utilities Derived from Multiattribute Utility Instruments. Medical Decision Making, 2017, 37, 262-272.	2.4	10
82	Temporal Trends and Factors Associated With the Inclusion of Patientâ€Reported Outcomes in Heart Failure Randomized Controlled Trials: A Systematic Review. Journal of the American Heart Association, 2021, 10, e022353.	3.7	10
83	Routine systematic sampling versus targeted sampling during endobronchial ultrasound: A randomized feasibility trial. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 254-261.e1.	0.8	10
84	Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore. Value in Health Regional Issues, 2012, 1, 46-53.	1.2	9
85	Measuring health-related quality-of-life for Alzheimer's disease using the general public. Quality of Life Research, 2012, 21, 593-601.	3.1	9
86	Cost-Effectiveness of Pharmaceutical Management for Osteoarthritis Pain. Drugs and Aging, 2013, 30, 277-284.	2.7	9
87	Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia. Saudi Journal of Gastroenterology, 2021, 27, 208.	1.1	9
88	RAVAL trial: Protocol of an international, multi-centered, blinded, randomized controlled trial comparing robotic-assisted versus video-assisted lobectomy for early-stage lung cancer. PLoS ONE, 2022, 17, e0261767.	2.5	9
89	Validation of the Comprehensive ICF Core Set for Osteoarthritis (OA) in patients with knee OA: a Singaporean perspective. Journal of Rheumatology, 2007, 34, 2301-7.	2.0	9
90	Assessment of Preference for Hormonal Treatment–Related Health States among Patients with Breast Cancer. Value in Health Regional Issues, 2014, 3, 27-32.	1.2	8

#	Article	lF	CITATIONS
91	Preference-based disease-specific health-related quality of life instrument for glaucoma: a mixed methods study protocol. BMJ Open, 2016, 6, e012732.	1.9	8
92	Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. European Journal of Health Economics, 2017, 18, 967-977.	2.8	8
93	Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada. PharmacoEconomics - Open, 2018, 2, 19-29.	1.8	8
94	Conditionally Funded Field Evaluations and Practical Trial Design Within a Health Technology Assessment Framework. Journal of the American College of Radiology, 2009, 6, 324-331.	1.8	7
95	Conditionally Funded Field Evaluations: PATHs Coverage with Evidence Development Program for Ontario. Value in Health, 2010, 13, S8-S11.	0.3	7
96	Scoring the 5-Level EQ-5D. Medical Decision Making, 2013, 33, 567-578.	2.4	7
97	How different are composite and traditional TTO valuations of severe EQ-5D-5L states?. Quality of Life Research, 2016, 25, 2101-2108.	3.1	7
98	Can the general public use vignettes to discriminate between Alzheimer's disease health states?. BMC Geriatrics, 2016, 16, 36.	2.7	7
99	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. European Journal of Health Economics, 2021, 22, 723-733.	2.8	7
100	Pulmonary Rehabilitation With Balance Training for Fall Reduction in Chronic Obstructive Pulmonary Disease: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2017, 6, e228.	1.0	7
101	Cost-effectiveness of eltrombopag versus intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Advances, 2021, , .	5.2	7
102	A look back at the first wave of COVID-19 in China: A systematic review and meta-analysis of mortality and health care resource use among severe or critical patients. PLoS ONE, 2022, 17, e0265117.	2.5	7
103	A pragmatic pilot randomized trial to investigate the effectiveness of behavioural activation group therapy in reducing depressive symptoms and improving quality of life in patients with depression: the BRAVE pilot trial protocol. Pilot and Feasibility Studies, 2015, 1, 39.	1.2	6
104	Guidelines that use the GRADE approach often fail to provide complete economic information for recommendations: A systematic survey. Journal of Clinical Epidemiology, 2021, 136, 203-215.	5.0	6
105	Patient Management, and Time and Health Care Resource Utilization Associated with the Use of Intravenous Bisphosphonates For Patients with Metastatic Bone Disease: A Delphi Study. Hospital Practice (1995), 2012, 40, 131-137.	1.0	5
106	Time and Labor Costs Associated With Administration of Intravenous Bisphosphonates for Breast or Prostate Cancer Patients With Metastatic Bone Disease: A Time and Motion Study. Hospital Practice (1995), 2014, 42, 38-45.	1.0	5
107	Health literacy and logical inconsistencies in valuations of hypothetical health states: results from the Canadian EQ-5D-5L valuation study. Quality of Life Research, 2017, 26, 1483-1492.	3.1	5
108	Preference-based Glaucoma-specific Health-related Quality of Life Instrument: Development of the Health Utility for Glaucoma. Journal of Glaucoma, 2018, 27, 585-591.	1.6	5

#	Article	IF	CITATIONS
109	Canada's Amendment to Patented Drug Price Regulation. JAMA - Journal of the American Medical Association, 2019, 321, 1565.	7.4	5
110	Latent Class Models Reveal Poor Agreement between Discrete-Choice and Time Tradeoff Preferences. Medical Decision Making, 2019, 39, 421-436.	2.4	5
111	Disease-specific Preference-based Measure of Glaucoma Health States: HUG-5 Psychometric Validation. Journal of Glaucoma, 2019, 28, 593-600.	1.6	5
112	Development of Clinical Vignettes to Describe Alzheimer's Disease Health States: A Qualitative Study. PLoS ONE, 2016, 11, e0162422.	2.5	5
113	A Computer-Assisted Personal Interview App in Research Electronic Data Capture for Administering Time Trade-off Surveys (REDCap): Development and Pretest. JMIR Formative Research, 2018, 2, e3.	1.4	5
114	Feasibility of an altruistic sperm donation program in Canada: results from a population-based model. Reproductive Health, 2017, 14, 8.	3.1	4
115	Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size. Medical Decision Making, 2018, 38, 26-33.	2.4	4
116	Minimally important difference and predictors of change in quality of life in type 2 diabetes: A communityâ€based survey in China. Diabetes/Metabolism Research and Reviews, 2018, 34, e3053.	4.0	4
117	Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation. Pharmacoeconomics, 2018, 36, 883-888.	3.3	4
118	International phase 1 study protocol to develop a health state classification system for a preference-based measure for women with breast cancer: the BREAST-Q Utility module. BMJ Open, 2020, 10, e034451.	1.9	4
119	Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy (DASH-TOP): a sequential explanatory mixed methods pilot study protocol. BMJ Open, 2021, 11, e046021.	1.9	4
120	Patientâ€Reported Outcomes and Patientâ€Reported Experience of Patients With Atrial Fibrillation in the IMPACTâ€AF Clinical Trial. Journal of the American Heart Association, 2021, 10, e019783.	3.7	4
121	More work needed on decision analysis for shared decision-making: A scoping review. Journal of Clinical Epidemiology, 2022, 141, 106-120.	5.0	4
122	A Systematic Literature Review of Health Utility Values in Breast Cancer. Medical Decision Making, 2022, 42, 704-719.	2.4	4
123	Comparison of 4-Year Health Care Expenditures Associated With Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. JAMA Network Open, 2021, 4, e2122079.	5.9	3
124	Model-based economic evaluation for medical decision making: learn from the past and prepare for the future. Journal of Thoracic Disease, 2013, 5, 209-10.	1.4	3
125	Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC). Clinical Genitourinary Cancer, 2022, 20, e353-e361.	1.9	3
126	The economics of adalimumab for ulcerative colitis. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 373-377.	1.4	2

#	Article	IF	CITATIONS
127	Using Both Time Tradeoff and Discrete Choice Experiments in Valuing the EQ-5D: Impact of Model Misspecification on Value Sets. Medical Decision Making, 2020, 40, 483-497.	2.4	2
128	Small differences in EQ-5D-5L health utility scores were interpreted differently between and within respondents. Journal of Clinical Epidemiology, 2022, 142, 133-143.	5.0	2
129	An Exploratory Analysis of Predictors of Concordance Between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta. Healthcare Policy, 2020, 15, 90-101.	0.6	2
130	Fighting COVID-19: a qualitative study into the lives of intensive care unit survivors in Wuhan, China. BMJ Open, 2022, 12, e055365.	1.9	2
131	Transforming challenges into opportunities: conducting health preference research during the COVID-19 pandemic and beyond. Quality of Life Research, 2022, 31, 1191-1198.	3.1	1
132	Indirectness (transferability) is critical when considering existing economic evaluations for GRADE clinical practice guidelines: a systematic review. Journal of Clinical Epidemiology, 2022, 148, 81-92.	5.0	1
133	China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population. Pharmacoeconomics, 2022, 40, 957-969.	3.3	1
134	Cost Effectiveness of Treatment Options for Early Prostate Cancer: Can We Put the Puzzle Pieces Together?. European Urology, 2013, 63, 411-412.	1.9	0
135	P4â€165: COSTâ€UTILITY ANALYSIS OF DEMENTIA CARE MANAGEMENT: RESULTS OF THE CLUSTERâ€RANDOMIZ CONTROLLED, INTERVENTIONAL TRIAL DELPHIâ€MV. Alzheimer's and Dementia, 2018, 14, P1502.	CED.8	0
136	3125 steps to perfect health: a nonparametric approach to developing the EQ-5D-5L value set. Quality of Life Research, 2020, 29, 3109-3118.	3.1	0
137	Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT). Pharmacoeconomics, 2021, 39, 1075-1084.	3.3	0
138	Quantifying the impacts of human mobility restriction on the spread of coronavirus disease 2019: an empirical analysis from 344 cities of China. Chinese Medical Journal, 2021, 134, 2438-2446.	2.3	0
139	Methodologic and Reporting Quality of Economic Evaluations in Hand and Wrist Surgery: A Systematic Review. Plastic and Reconstructive Surgery, 2022, 149, 453e-464e.	1.4	0
140	How Do Health Schemas Inform Healthy Behaviours During Pregnancy? Qualitative Findings from the Be Healthy in Pregnancy (BHIP) Study. Maternal and Child Health Journal, 2022, , 1.	1.5	0
141	Time-Specific Differences in Stated Preferences for Health in the United States. Medical Care, 2022, Publish Ahead of Print, .	2.4	0
142	Responsiveness of the HUG-5 in an outpatient clinic: a 12-month randomised feasibility study protocol. BMJ Open, 2022, 12, e061057.	1.9	0